PHARMA PROJECTS
Biomonitoring Futures Project
With support from the Robert Wood Johnson Foundation, IAF developed the Biomonitoring Futures Project (BFP), which identifies trends in emerging biomonitoring technologies, explores them in the context of healthy living and prevention,and examines how they can reduce health care disparities particularly for cancer and diabetes. BFP also provides forecasts for future development and use of these technologies. Other output included the Biomonitoring Platform Assessment Report, the Health Information Systems Report, and the Final Report and Recommendations.
The 2029 Project: Achieving an Ethical Future for Biomedical R&D
This project showcases the dramatic advances that are likely to occur across the spectrum of biomedical research and development activities. It forecasts that a wide array of achievements in science will be enabled by an ethical evolution. After scanning the scientific literature, interviewing dozens of scientists and holding meetings focused on 2029, IAF anticipates a culture change. An emerging ethical concern for global health will create the context for medical science to realize its full potential, which will culminate in a Health Advocate Avatar. Click here for the executive summary or here for the full report (large file).
Co-evolution: Innovation and Regulation of Medical Products
IAF facilitated a meeting of leaders from regulation and industry to explore the future environment for the innovation and regulation of medical products. Participants used a series of thirteen forecasts for the next decade to stimulate thinking. Click here to see the report.
Optimal Futures for Risk Evaluation and Mitigation Strategies (REMS)
In September 2009, in conjunction with the Society for Women's Health Research, IAF facilitated a workshop of regulators, industry, academics, and consumer advocates to explore the optimal futures for the FDA's new Risk Evaluation and Mitigation Strategies (REMS). View the PDF report here.
Drug Diagnostic Strategy for Pfizer
Adapted from the concept of wargaming, simulations can explore new stakeholder engagement and collaboration opportunities; test strategies before deployment to know the risks and uncertainties in advance; and optimize team decision-making. In this simulation, IAF Senior Associate Dr. Ben Sheppard evaluated the optimal combination and partnerships of drug diagnostic companies with Pfizer. Four diagnostic companies were invited to develop mock deals with a Pfizer team covering a 10 year period to assess the consequences of the decisions made. The simulation accelerated the decision making process and identified how the future healthcare reform led by then-to-be-elected Barack Obama could impact the pharmaceutical industry.